Introduction
Materials and methods
Patient selection
Targeted RNA sequencing
Bioinformatics analysis
Fusion confirmation
Cytogenetics and immunophenotypic analysis
Results
Detection of EP300-ZNF384 fusion in patients
Case | Gender | Age (years) | Samples obtained at | Category | Initial WBC (*109/L) | BM blast | Karyotype | Immunophenotype |
---|---|---|---|---|---|---|---|---|
1 | Female | 28 | Rel (1st) | B-ALL | 3.5 | 76% | 46,XX[10] | CD19+/CD34+/CD22+/CD38+/CD58+/CD33+/CD123+/HLA-DR+/CD10-/CD20-/CD13-/CD15- |
2 | Female | 63 | Dx | B-ALL | 12.83 | 89.2% | 46,XX[5] | CD19+/CD34+/CD33+/HLA-DR+/CD79a+partial/CD38+/CD58+/CD22+/CD13+/CD10-/CD20-/MPO-/CD3- |
3 | Female | 47 | Dx | B-ALL | 4.86 | 87.2% | 46,XX[5] | CD19+/CD34+/CD38+/CD33+/CD22+/CD58+/HLA-DR+/CD79a+/CD20-/MPO-/CD15-/CD10-/CD13-/CD3- |
4 | Female | 19 | Dx | B-ALL | 8.65 | 86% | 45,X,-X[9] /46,XX[26] /Subdiploid[7] | CD19+/CD34+/CD38+/CD33+/CD22+/CD58+/HLA-DR+/CD79a+/CD15+/CD20-/MPO-/CD13-/CD10-/CD3-/CD117- |
5 | Female | 43 | Dx | B-ALL | 2.7 | 79.2% | 46,XX[20] | CD19+/CD34+/CD38+/CD22+/CD58+/CD10+partial/MPO+/HLA-DR+/CD79a+/CD20-/CD15-/CD33-/CD13-/CD16-/CD11b-/CD14-/CD64-/CD3- |
6 | Male | 17 | Dx | B-ALL | 10.91 | 79.6% | 46,XY,9qh+[20] | CD19+/CD34+/CD38+/CD33+/CD22+/CD13+/CD58+/CD10+/HLA-DR+/CD79a+/CD20-/MPO-/CD3- |
7 | Male | 20 | Dx | B-ALL | 21.77 | 96% | 46,XY[5] | CD19+/CD34+/CD38+/CD33+/CD22+/CD58+/CD10+/HLA-DR+/CD79a+/CD20-/MPO-/CD15-/CD13-/CD123-/IgM-/CD3- |
8 | Male | 32 | Rel (2nd) | B-ALL | 2.67 | 97.2% | 46,XY[20] | CD19+/CD34+/CD10+/CD22+/CD38+/CD58+/CD13+ partial/CD20- |
9 | Male | 27 | Dx | B-ALL | 41.34 | 96% | 46,XY[20] | CD19+/CD34+/CD38+/CD10+/CD22+/CD13+/CD58+/CD33+/HLA-DR+/CD79a+/CD20-/MPO-/CD3- |
10 | Male | 38 | Dx | B-ALL | 118 | 93.6% | 46,XY,t(11;12) (p11;p13) | CD19+/CD34+/CD38+/CD58+/CD22+/CD13+/CD33+/CD79a+/CD10+ partial/CD20-/MPO-/CD3- |
Case | Fusion | Breakpoint | Treatment | Chemotherapy regimen | CR | Current status | Follow-up from determination of EP300-ZNF384 fusion (months) | Follow-up from diagnosis (months) |
---|---|---|---|---|---|---|---|---|
1 | EP300-ZNF384 | Ex6-Ex3 | Chemotherapy, Allo-HSCT | VDCLP | Yes | Alive | 26 | 84 |
2 | EP300-ZNF384 | Ex6-Ex3 | Chemotherapy | VDCLP | Yes | Alive | 30 | 30 |
3 | EP300-ZNF384 | Ex6-Ex3 | Chemotherapy, Allo-HSCT | VDCLP | Yes | Alive | 24 | 24 |
4 | EP300-ZNF384 | Ex6-Ex3, Ex6-Ex2 | Chemotherapy | VDCLP-like | Yes | Alive | 19 | 19 |
5 | EP300-ZNF384 | Ex6-Ex3 | Chemotherapy | MAVP | No | Died | 1 | 1 |
6 | EP300-ZNF384 | Ex6-Ex3, Ex6-Ex2 | Chemotherapy | VDCLP | Yes | Alive | 20 | 20 |
7 | EP300-ZNF384 | Ex6-Ex3 | Chemotherapy, CarT, Allo-HSCT | VDCLP | No | Died | 21 | 21 |
8 | EP300-ZNF384 | Ex6-Ex2 | Chemotherapy, CarT, B-ALLo-HSCT | VACLP | No | Died | 35 | 83 |
9 | EP300-ZNF384 | Ex6-Ex3 | Chemotherapy, Allo-HSCT | VDCLP | Yes | Alive | 36 | 36 |
10 | EP300-ZNF384 | Ex6-Ex3 | Chemotherapy, Allo-HSCT | VDCLP | Yes | Alive | 46 | 46 |